.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The five-year STAMPEDE follow-up compared intensive medical and lifestyle therapy with bariatric surgical procedures in patients with type 2 diabetes and obesity. The study showed that surgery provided more durable improvement in glycemic control and greater reductions in diabetes medication use than medical therapy alone. Importantly, the benefit persisted over several years rather than being limited to the early postoperative period. The trial helped establish metabolic surgery as more than a weight-loss intervention: in selected patients, it can substantially change the course of type 2 diabetes. For surgeons, the key message is patient selection and multidisciplinary follow-up. Surgical eligibility, nutritional monitoring, diabetes medication adjustment and long-term metabolic surveillance all matter. The study does not mean surgery replaces medical care for every patient with obesity and diabetes; rather, it provides randomized evidence that metabolic surgery can deliver durable disease-modifying benefits in appropriate candidates. These findings should be incorporated into discussions with endocrinology, internal medicine and bariatric teams when considering treatment pathways for patients with difficult-to-control diabetes.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The five-year STAMPEDE follow-up compared intensive medical and lifestyle therapy with bariatric surgical procedures in patients with type 2 diabetes and obesity. The study showed that surgery provided more durable improvement in glycemic control and greater reductions in diabetes medication use than medical therapy alone. Importantly, the benefit persisted over several years rather than being limited to the early postoperative period. The trial helped establish metabolic surgery as more than a weight-loss intervention: in selected patients, it can substantially change the course of type 2 diabetes. For surgeons, the key message is patient selection and multidisciplinary follow-up. Surgical eligibility, nutritional monitoring, diabetes medication adjustment and long-term metabolic surveillance all matter. The study does not mean surgery replaces medical care for every patient with obesity and diabetes; rather, it provides randomized evidence that metabolic surgery can deliver durable disease-modifying benefits in appropriate candidates. These findings should be incorporated into discussions with endocrinology, internal medicine and bariatric teams when considering treatment pathways for patients with difficult-to-control diabetes.
4 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
